+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cancer Immunotherapy Market - Forecasts from 2018 to 2023

  • ID: 4661620
  • Report
  • September 2018
  • Region: Global
  • 102 pages
  • Knowledge Sourcing Intelligence LLP

FEATURED COMPANIES

  • Cellectis SA
  • CytomX Therapeutics, Inc.
  • Eisai Co., Ltd.
  • Jounce Therapeutics, Inc.
  • Nektar
  • Pfizer, Inc.
The global cancer immunotherapy market is projected to expand at a CAGR of 12.98% over the forecast period of 2017-2023. Cancer immunotherapy is a treatment where the human body makes use of its natural defense mechanism also known as the immune system in order to identify, attack and kill cancer cells. There are many companies working in collaborations for designing the drugs for cancer immunotherapy. Adopting unhealthy living conditions and prevalence of cancer are driving the growth of the global cancer immunotherapy market.

For boosting the immune system certain therapies are used, for example, the BCG therapy which is injected directly into the bladder and is found effective in about 70 percent of patients with early-stage bladder cancer. Other therapies include cytokines, radioimmunotherapy, and oncolytic virus therapy.

National Cancer Institute of U.S. Department of Health and Human Services is at the forefront of developing immunotherapies and is also working towards the understanding of the unknown mechanisms in immune responses against a specific cancer type and specific patient.

One of the NCI-funded research has led to the identification of biomarkers which can help in determining the type of patients more likely to respond to the checkpoint inhibitor therapy. The biomarkers are PD-L1 and a genetic feature called microsatellite instability. Hence, it will become easier to detect patients who have these biomarkers and will respond to certain checkpoint inhibitors in comparison to patients lacking these biomarkers.

The cancer immunotherapy market is anticipated to grow in the Asia Pacific region due to the growing patient pool in the country accompanied by the growing cancer awareness, technological advancements and growing demand from the emerging economies like India and China. While North America is expected to show a major market share owing to the adoption of early innovations and the presence of key market players in this region followed by Europe.

Major industry players profiled as part of the report are Bristol-Myers Squibb Company, Eisai Co., Ltd., Nektar, and Servier among others.

Segmentation

The global cancer immunotherapy market has been analyzed through following segments:

By Type

Monoclonal antibodies (MABs)
Checkpoint Inhibitors
Cytokines
Cancer vaccines
Adoptive Cell transfer

By Application

Skin cancer
Lung cancer
Leukemias
Bladder cancer
Others

By Geography

North America

US
Canada
Mexico
Others

South America
Brazil
Argentina
Others

Europe
United Kingdom
Germany
France
Italy
Others

Middle East and Africa
Israel
UAE
Saudi Arabia
Others

Asia Pacific
China
India
Japan
South Korea
Australia
Others
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Cellectis SA
  • CytomX Therapeutics, Inc.
  • Eisai Co., Ltd.
  • Jounce Therapeutics, Inc.
  • Nektar
  • Pfizer, Inc.
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE
5.1. Monoclonal antibodies (MABs)
5.2. Checkpoint Inhibitors
5.3. Cytokines
5.4. Cancer vaccines
5.5. Adoptive Cell transfer

6. GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION
6.1. Skin cancer
6.2. Lung cancer
6.3. Leukemias
6.4. Bladder cancer
6.5. Others

7. GLOBAL CANCER IMMUNOTHERAPY MARKET BY GEOGRAPHY
7.1. North America
7.1.1. United States
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. Italy
7.3.4. United Kingdom
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Israel
7.4.2. Saudi Arabia
7.4.3. UAE
7.4.4. Others
7.5. Asia Pacific
7.5.1. Japan
7.5.2. China
7.5.3. India
7.5.4. Australia
7.5.5. South Korea
7.5.6. Others

8. COMPETITIVE INTELLIGENCE
8.1. Market Share Analysis
8.2. Recent Deals and Investment
8.3. Strategies of Key Players

9. COMPANY PROFILES
9.1. Servier
9.1.1. Company Overview
9.1.2. Financials
9.1.3. Products and Services
9.1.4. Recent Developments
9.2. Sanofi
9.2.1. Company Overview
9.2.2. Financials
9.2.3. Products and Services
9.2.4. Recent Developments
9.3. Xencor
9.3.1. Company Overview
9.3.2. Financials
9.3.3. Products and Services
9.3.4. Recent Developments
9.4. Jounce Therapeutics, Inc.
9.4.1. Company Overview
9.4.2. Financials
9.4.3. Products and Services
9.4.4. Recent Developments
9.5. Pfizer Inc.
9.5.1. Company Overview
9.5.2. Financials
9.5.3. Products and Services
9.5.4. Recent Developments
9.6. Cellectis SA
9.6.1. Company Overview
9.6.2. Financials
9.6.3. Products and Services
9.6.4. Recent Developments
9.7. CytomX Therapeutics, Inc.
9.7.1. Company Overview
9.7.2. Financials
9.7.3. Products and Services
9.7.4. Recent Developments
9.8. Bristol-Myers Squibb Company
9.8.1. Company Overview
9.8.2. Financials
9.8.3. Products and Services
9.8.4. Recent Developments
9.9. Nektar
9.9.1. Company Overview
9.9.2. Financials
9.9.3. Products and Services
9.9.4. Recent Developments
9.10. Eisai Co., Ltd.
9.10.1. Company Overview
9.10.2. Financials
9.10.3. Products and Services
9.10.4. Recent Developments
Note: Product cover images may vary from those shown
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Nektar
  • Servier
  • Sanofi
  • Xencor
  • Jounce Therapeutics, Inc.
  • Pfizer, Inc.
  • Cellectis SA
  • CytomX Therapeutics, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll